Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery

Summary

Patients undergoing major orthopedic surgery are at an increased risk of thromboembolism even after the acute postoperative phase. Therefore, prolonged thromboprophylaxis is currently recommended and widely used. The length of hospital stay after major orthopedic surgery is steadily decreasing and most patients are transferred to specialized rehabilitation centers in the early postoperative phase. Consequently, thromboprophylaxis is usually given during the rehabilitation period. Previously there have been no systematic studies of how many patients with asymptomatic thrombosis are transferred to a rehabilitation center or how many patients develop deep vein thrombosis (DVT) during rehabilitation. In the present study, 238 patients who had undergone major orthopedic surgery were examined by compression ultrasonography on day 1 or 2 and on day 20 of their rehabilitation phase in order to detect asymptomatic proximal DVT. Sonograms were read centrally with blinding to the clinical course of the patients. All patients received standard thromboprophylaxis during the acute postoperative phase. Prolonged thromboprophylaxis with enoxaparin was given during the rehabilitation phase. The mean duration of thromboprophylaxis was 36.8 days. At admission to the rehabilitation center, proximal DVT was identified in 16 patients (6.7%). New proximal DVT at discharge from the rehabilitation center was identified in 3.2% of patients following prolonged thromboprophylaxis with enoxaparin. In conclusion, a considerable percentage of patients with asymptomatic proximal DVT are transferred to rehabilitation centers following major orthopedic surgery. Using prolonged thromboprophylaxis, new proximal DVTs will still develop during rehabilitation, but at a low rate.

Keywords

Ultrasonography - orthopedic surgery - venous thromboembolism - low-molecular-weight heparin

• References

• 1 Pauschert R, Diehm C, Stammler F. Guidelines for prevention of thrombosis in orthopedics [in German].. Z Orthop Ihre Grenzgeb 1998; 136: 471-9.
• 2 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.. Chest 2004; 126: 338S-400S.
• 3 Bergqvist D, Benoni G, Bjorgell O. et al. Low-molecular- weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.. N Engl J Med 1996; 335: 696-700.
• 4 Comp PC, Spiro TE, Friedman RJ. et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.. J Bone Joint Surg Am 2001; 83-A: 336-45.
• 5 Dahl OE, Andreassen G, Aspelin T. et al. Prolonged thromboprophylaxis following hip replacement surgery— results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).. Thromb Haemost 1997; 77: 26-31.
• 6 Hull RD, Pineo GF, Francis C. et al. Low-molecularweight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Investigators.. Arch Intern Med 2000; 160: 2208-15.
• 7 Hull RD, Pineo GF, Stein PD. et al. Extended out-ofhospital low-molecular-weight heparin prophylaxisagainst deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.. Ann Intern Med 2001; 135: 858-69.
• 8 Lassen MR, Borris LC, Anderson BS. et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study.. Thromb Res 1998; 89: 281-7.
• 9 Planes A, Vochelle N, Darmon JY. et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: doubleblind randomised comparison of enoxaparin versus placebo.. Lancet 1996; 348: 224-8.
• 10 Wissenschaftlich begründete Leitlinien für Diagnostik und Therapie: Science-based Guidelines for Diagnostics and Therapy.. AWMF online. http://www.uni-duesseldorf.de/www/awmf/ll/
• 11 Kolb G, Bodamer I, Galster H. et al. Long-term Thromboprophylaxis Study Group. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.. Thromb Haemost 2003; 90: 1100-5.
• 12 Schmidt B, Michler R, Klein M. et al. Ultrasound screening for distal vein thrombosis is not beneficial after major orthopedic surgery. A randomized controlled trial.. Thromb Haemost 2003; 90: 949-54.
• 13 Robinson KS, Anderson DR, Gross M. et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the postarthroplasty screening study. A randomized, controlled trial.. Ann Intern Med 1997; 127: 439-45.
• 14 Ginsberg JS, Caco CC, Brill-Edwards PA. et al. Venous thrombosis in patients who have undergone major hip or knee surgery: detection with compression US and impedance plethysmography.. Radiology 1991; 181: 651-4.
• 15 Robinson KS, Anderson DR, Gross M. et al. Accuracy of screening compression ultrasonography and clinical examination for the diagnosis of deep vein thrombosis after total hip or knee arthroplasty.. Can J Surg 1998; 41: 368-73.
• 16 Lin PP, Graham D, Hann LE. et al. Deep venous thrombosis after orthopedic surgery in adult cancer patients.. J Surg Oncol 1998; 68: 41-7.
• 17 Lensing AW, Doris CI, McGrath FP. et al. A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis.. Arch Intern Med 1997; 157: 765-8.
• 18 Vaitkus PT, Leizorovicz A, Cohen AT. et al PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients.. Thromb Haemost 2005; 93: 76-9.